Santarus to Launch Drug for Type 2 Diabetes

Xconomy San Diego — 

San Diego-based Santarus (NASDAQ: SNTS) said it has acquired exclusive rights from S2 Therapeutics of Bristol, TN, and VeroScience of Tiverton, RI to make and sell bromocriptine mesylate (Cycloset) tablets in the U.S. The Food and Drug Administration has approved the prescription drug as an adjunct to diet and exercies to improve glycemic control in adults with type 2 diabetes. Santarus said it expects to launch the drug commercially in November 2010.